|
Resolution: standard / high Figure 4.
Changes in total Sharp score in patients with active rheumatoid arthritis who were
given one of two dosages of adalimumab or placebo. Reproduced with permission from
John Wiley & Sons, Inc. [36]. © 2002 American College of Rheumatology
Schwartzman et al. Arthritis Res Ther 2004 6(Suppl 2):S3 doi:10.1186/ar1013 |
